replicor

[tinknocker]

So what was the outcome of Replicor..Any results?

[studyforhope]

This is the same drug that was used in the second Bangladesh trial on hbv mono e ag positiv patients. The differences are a much longer planned immunotherapy add on, in the hope also to improve hbv svr rates.

[StephenCastlecrag]

So has it been confirmed that rep2139-ca block the release of HBsAg and HDV virions, but not HBV virions?
Thanks.

[studyforhope]

The dramatic effect on HDV gives replicor a much better chance for further development and ultimately approval. BUT the longer term outcome of this even on hdv has to be awaited, viruses bounce back if even a tiny trace is left in the liver. Since almost a year of interferon add on is planned,  there is a chance, however, of good SVR rates. It remains to be seen, if due to the high instability of the HDV RNA genome, a selective eradication or control of HDV is possible. And how high the hbv svr rate will be. We will have to wait for a long time to know the answers to these critical questions.

[sorte]

Using the same drug for HBV monoinfection should give similar results or better ?

[studyforhope]

Unfortunately it will be much harder to establish permanent immune control in e antigen negative patients.

[studyforhope]

No the key mechanism new here is the reduction in HDV virions, that operates in the same fashion as the blockage of HBsAg release. Thus it is not the reduction of HBsAg that drives indirectly the viral load reduction as in hbv, but the delta virions themselves are retained and thus HDV virions drop in parallel with hbsag, but NOT because of it.
Thus the HDV vl reduction is much more profound than the hbv virion reduction in serum. HDV reinfection will be dramatically reduced and then consequently the immune attack against the delta antigen, which causes the severity of this disease.